STOCK TITAN
  1. Home
  2. News
  3. MRNA

Moderna Inc - MRNA STOCK NEWS

Welcome to our dedicated news page for Moderna (Ticker: MRNA), a resource for investors and traders seeking the latest updates and insights on Moderna.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Moderna's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Moderna's position in the market.

News
Merck and Moderna Initiate INTerpath-002, a Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Certain Types of Resected Non-Small Cell Lung Cancer
Rhea-AI Summary
Merck (MRK) and Moderna (MRNA) have initiated the second clinical trial in the INTerpath program, a Phase 3 randomized clinical trial evaluating V940 (mRNA-4157) in combination with KEYTRUDA as adjuvant treatment in patients with completely resected non-small cell lung cancer. This represents a rapid expansion in research for individualized neoantigen therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.6%
Tags
clinical trial
-
News
Moderna Reviews its Environmental, Social and Governance (ESG) Progress and Ambitions at Second ESG Investor Event
Rhea-AI Summary
Moderna, Inc. (NASDAQ:MRNA) will provide an update on its Environmental, Social and Governance (ESG) strategy at its second ESG Investor Event. The company emphasizes its commitment to global health, environmental sustainability, and employee and community welfare. Moderna's ESG strategy focuses on medicines for patients, environmental sustainability, employee culture, community impact, and governance and ethics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.81%
Tags
none
-
News
Moderna to Host Second Environmental, Social and Governance (ESG) Investor Event on December 7th, 2023
Rhea-AI Summary
Moderna, Inc. (NASDAQ: MRNA) to Host Second Virtual ESG Investor Event on December 7, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.54%
Tags
conferences
News
Moderna to Present at Upcoming Conferences in November 2023
Rhea-AI Summary
Moderna, Inc. (MRNA) to participate in key investor conferences including 2023 UBS Global Biopharma Conference, Jefferies London Healthcare Conference, and 35th Annual Piper Sandler Healthcare Conference. Live webcasts and replays available on Moderna's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.57%
Tags
conferences
-
News
Moderna Highlights its Digital and AI Strategy and Progress at Second Digital Investor Event
Rhea-AI Summary
Moderna, Inc. (NASDAQ:MRNA) to present its comprehensive AI and digital strategy at its second Digital Investor Event. The company will showcase how AI continues to transform the organization, highlighting its leading position in AI-powered innovation and its ability to harness the power of AI to improve efficiency and scalability across the value chain.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.15%
Tags
AI
-
News
Moderna Tops BioSpace’s Best Places to Work Ranking for Third Consecutive Year
Rhea-AI Summary
Moderna, Inc. (NASDAQ:MRNA) has been ranked as the number one large employer in BioSpace's 2024 Best Places to Work report for the third consecutive year. The company's CEO, Stéphane Bancel, expressed pride in this recognition, highlighting the unique culture and investments in the team. Moderna's commitment to employee development, well-being, and belonging has been acknowledged, with significant investments made in 2023 to support the rapid advancement of its pipeline of mRNA medicines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.21%
Tags
none
News
Moderna Reports Third Quarter 2023 Financial Results and Provides Business Updates
Rhea-AI Summary
Moderna reports Q3 2023 revenues of $1.8 billion, expects 2023 revenues of at least $6 billion. Spikevax U.S. market share increases to 45%. Company anticipates 2024 revenue of approximately $4 billion and return to growth in 2025. Manufacturing capacity resized to improve future cost of sales. Net loss of $3.6 billion primarily driven by non-cash charges related to resizing and tax valuation allowance. Late-stage pipeline has six Phase 3 programs. Company expects to break even in 2026 through product launches and disciplined investment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.52%
Tags
earnings
-
News
CEPI and Moderna Harness mRNA Technology to Advance 100 Days Mission
Rhea-AI Summary
The Coalition for Epidemic Preparedness Innovations (CEPI) and Moderna, Inc. have formed a partnership to accelerate the development of vaccines against viral disease outbreaks. The partnership aims to expand the infectious disease targets for mRNA vaccine technology and strengthen pandemic preparedness. The partnership will begin with a project to test AI-generated antigen designs for high-risk viral families. CEPI-funded researchers will send their designs to Moderna, who will manufacture the vaccine candidates for preclinical testing. The partnership is committed to enabling equitable access to the vaccine outputs, with affordable prices for low- and middle-income countries.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3%
Tags
none
-
News
Moderna Named a Top Employer by Science for Ninth Consecutive Year
Rhea-AI Summary
Moderna ranked as one of the top employers in the biopharmaceutical industry for the ninth consecutive year. The company was recognized for its commitment to innovation, employee respect, and social responsibility.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.02%
Tags
none
News
Moderna Announces First Participant Dosed in Phase 3 Study of mRNA-1083, a Combination Vaccine Against Influenza and COVID-19
Rhea-AI Summary
Moderna initiates Phase 3 trial for mRNA-1083, a combination vaccine candidate against influenza and COVID-19
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.42%
Tags
clinical trial covid-19
Stock MRNA logo
Moderna Inc

NYSE:MRNA

MRNA Rankings

#296 Ranked by Market Cap
#4725 Ranked by Stock Gains
N/A Ranked by Dividends

MRNA Stock Data

40.26B
344.86M
9.63%
73.16%
5.6%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Cambridge

About MRNA

moderna is pioneering messenger rna therapeutics™, an entirely new in vivo drug modality that produces human proteins or antibodies inside patient cells, which are in turn active intracellularly or secreted. this breakthrough platform addresses currently undruggable targets, and offers a superior alternative to existing drug modalities for a wide range of disease conditions. moderna has developed a broad intellectual property estate including more than 200 patent applications with more than 10,000 claims ranging from novel nucleotide chemistries to specific drug compositions. the company plans to develop and commercialize its innovative mrna drugs—initially for rare diseases and oncology—while partnering drug candidates in other therapeutics areas in order to rapidly deliver this innovation to patients. based in cambridge, massachusetts, moderna is privately held and was founded in 2010 by flagship venturelabs in association with leading scientists from boston children’s hospital a